Martingale Asset Management L P Acquires Shares of 1,400 ICU Medical, Inc. (NASDAQ:ICUI)

Martingale Asset Management L P acquired a new stake in ICU Medical, Inc. (NASDAQ:ICUI) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,400 shares of the medical instruments supplier’s stock, valued at approximately $255,000.

Other institutional investors have also recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of ICU Medical by 4.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 42,742 shares of the medical instruments supplier’s stock valued at $7,788,000 after buying an additional 1,751 shares during the period. Public Sector Pension Investment Board increased its stake in shares of ICU Medical by 15.1% in the 3rd quarter. Public Sector Pension Investment Board now owns 51,854 shares of the medical instruments supplier’s stock valued at $9,449,000 after buying an additional 6,800 shares during the period. MetLife Investment Management LLC increased its stake in shares of ICU Medical by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 12,389 shares of the medical instruments supplier’s stock valued at $2,258,000 after buying an additional 6,981 shares during the period. BNP Paribas Financial Markets increased its stake in shares of ICU Medical by 16.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,997 shares of the medical instruments supplier’s stock valued at $1,275,000 after buying an additional 991 shares during the period. Finally, FMR LLC increased its stake in shares of ICU Medical by 2,676.6% in the 3rd quarter. FMR LLC now owns 104,094 shares of the medical instruments supplier’s stock valued at $18,968,000 after buying an additional 100,345 shares during the period. Institutional investors own 96.10% of the company’s stock.

Insider Buying and Selling at ICU Medical

In other news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $178.46, for a total value of $2,141,520.00. Following the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at $18,665,666.78. The trade was a 10.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director David C. Greenberg sold 972 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $158.11, for a total value of $153,682.92. Following the completion of the sale, the director now owns 5,037 shares in the company, valued at approximately $796,400.07. This trade represents a 16.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 40,364 shares of company stock valued at $6,869,878. Company insiders own 6.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th. Raymond James lifted their price objective on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. Jefferies Financial Group assumed coverage on ICU Medical in a research note on Monday, October 14th. They set a “hold” rating and a $183.00 price objective for the company. KeyCorp lifted their price objective on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 13th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research note on Wednesday, November 13th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $173.00.

ICU Medical Stock Down 0.0 %

NASDAQ:ICUI opened at $156.63 on Thursday. ICU Medical, Inc. has a 1 year low of $83.26 and a 1 year high of $196.26. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The stock has a market cap of $3.83 billion, a price-to-earnings ratio of -34.27 and a beta of 0.62. The stock has a 50-day moving average price of $173.90 and a two-hundred day moving average price of $148.43.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.